LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Inicio・Lista de Acciones・United Therapeutics Corp

United Therapeutics Corp

Cerrado

SectorSanidad

567.25 -0.12

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

559.78

Máximo

569.82

Métricas clave
By Trading Economics
Ingresos	-89M 275M
Ventas	-8.7M 782M
P/B Media del Sector	20.882 51.415
BPA	5.82
Margen de beneficios	35.176
Empleados	1,400
EBITDA	-176M 348M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+14.16% upside

Dividendos
By Dow Jones
Próximas Ganancias	29 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-476M 24B
Apertura anterior	567.37
Cierre anterior	567.25

Noticias sobre sentimiento de mercado

By Acuity

46%

54%

145 / 345 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

292.345 / 309.245 Soporte y Resistencia

United Therapeutics Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 may 2026, 23:10 UTC

Acciones populares

Stocks to Watch: Agilysys, XP

18 may 2026, 18:44 UTC

Principales Movimientos del Mercado

Claritev Shares Recover After Comments About DOJ

18 may 2026, 23:55 UTC

Ganancias

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 may 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 may 2026, 23:37 UTC

Charlas de Mercado

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 may 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 may 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

18 may 2026, 20:25 UTC

Ganancias

Correct: XP 1Q Total Client Assets BRL1.53T

18 may 2026, 20:23 UTC

Ganancias

XP 1Q Total Client Assets BRL1.53B

18 may 2026, 20:19 UTC

Ganancias

XP 1Q Adj EPS BRL2.49 >XP

18 may 2026, 20:19 UTC

Ganancias

XP 1Q Rev BRL4.73B >XP

18 may 2026, 19:10 UTC

Charlas de Mercado

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 may 2026, 19:00 UTC

Ganancias

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 may 2026, 18:52 UTC

Charlas de Mercado

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 may 2026, 18:17 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 may 2026, 17:22 UTC

Charlas de Mercado

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 may 2026, 16:57 UTC

Adquisiciones, fusiones, absorciones

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 may 2026, 16:57 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

18 may 2026, 16:57 UTC

Charlas de Mercado

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 may 2026, 16:54 UTC

Adquisiciones, fusiones, absorciones

Vinci Doesn't Set Out Financial Details of Deal

18 may 2026, 16:50 UTC

Adquisiciones, fusiones, absorciones

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 may 2026, 16:49 UTC

Adquisiciones, fusiones, absorciones

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 may 2026, 16:49 UTC

Adquisiciones, fusiones, absorciones

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 may 2026, 16:48 UTC

Adquisiciones, fusiones, absorciones

Vinci Buys Canada's Modern Group of Companies

Comparación entre iguales

Cambio de precio

United Therapeutics Corp previsión

Precio Objetivo

By TipRanks

14.16% repunte

Estimación a 12 Meses

Media 649.08 USD 14.16%

Máximo 738 USD

Mínimo 516 USD

De acuerdo con 13 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para United Therapeutics Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

13 ratings

Comprar

Mantener

Vender

De acuerdo con 13 analistas que ofrecen calificaciones bursátiles a para United Therapeutics Corp Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

292.345 / 309.245Soporte y Resistencia

Recent bullish events outweigh bearish events.

All events are bearish.

Sentimiento

By Acuity

145 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.